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ABSTRACT
Background &Objective: Breast cancer is the most common female malignancy. Detection of DNA 
of human papillomaviruses (HPVs) in breast carcinomas suggests that the virus may play a role 
in the pathogenesis of this disease. The aim of this study was to evaluate the frequency of HPVs 
genotypes 6, 11, 16, 18 and 31 in paraffin-embedded tissue samples of invasive breast carcinomas.
Methods: Three hundred and twenty six paraffin-embedded tissue samples of breast cancer were 
studied. PCR was performed using specific primers for HPV genotypes. 
Results: Of total 206 (63.2%) samples positive for Beta-globin gene, 54 (26.2%) were HPV-positive 
and 152 (73.8%) were negative for HPV. Distribution of HPV genotypes were as follows: 19 
(25.7%) were positive for genotype 11, 5 (6.8%) were positive for genotype 6; and 2 cases (2.7%) 
were positive for both genotypes 6 and 11. Samples were also screened for HPV genotypes 16, 18 
and 31 but none was positive.
Conclusion: The current study confirmed the association of HPV and breast cancer. However, all 
samples were negative for high-risk HPV types 16, 18 and 31. 
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Introduction
Human Papillomavirus (HPVs) can be transmitted between individuals through genitals, anal, mouth or breast 
(1). Breast cancer is the most common malignant 
tumor among women and the second highest 
cause of cancer-related death (2,3). Among 
Iranian women, mortality due to breast cancer is 
higher than deaths due to other kinds of cancer 
(4). More than 1,000,000 new cases are diagnosed 
each year in the United States of America and it 
caused about 458,000 deaths worldwide alone in 
2008(5). Although the incidence of breast cancer 
has almost doubled in the past four years in the 
United States, the death rate remained noticeably 
constant. The loss of cellular regulation that gives 
rise to most of cancers is due to genetic damages. 
Numerous factors, especially mutations, are 
considered the risk factors in the onset of cancer 
(6,7). These are often unknown mutations, which 
are inherited or acquired. Breast cancer is rare 
in people under 25 years unless a family history 
of breast cancer exist (8). The risk of breast 
cancer increases with age. Although there are 
many patients without a family history of breast 
cancer, 13% of women with a family history 
are found to develop breast cancer. This finding 
reinforces the probability of the involvement of 
other non-genetical factors (9,10). Exercising, 
using medication, breastfeeding, life style, stress, 
genetic aptitude for the disease and other factors 
may have role in the genesis of breast cancer 
(9, 11,12). Virus infection may be responsible 
for breast cancer. However, more studies are 
required to confirm their associations.
HPVs are small and are capable of causing warts 
in some vertebrates, including humans. Based 
on phylogenetic relationships and their role in 
benign and malignant cervical cancers, HPVs 
are classified into three categories: high-risk, 
medium-risk and low-risk. HPV types 16, 18 and 
45 fall into high-risk category while intermediate-
risk group includes HPV types 31, 33, 35, 39, 51, 
52, 53, 56, 58, 59, 66, 68, 73 and 82. Low-risk 
types include types 6, 11, 40, 42, 43, 44, 54, 61, 
70, 72 and 81. These viruses have the ability to 
cause cancer in humans and animals (13). Some 
HPVs cause cervical cancer and epithelial tumors 
(14-17). 
In the present study, the authors evaluated 326 
paraffin-embedded samples in order to identify 
possible relationships between HPV infection 
and manifestations and progressions of breast 
cancer.
Materials and Methods 
Sample collection 
After obtaining approval from ethics committee 
of Mashhad University of Medical Sciences, 
samples collected between August 2002 and 
September 2012 from pathology departments 
of Imam Reza and Qaem hospitals in the city of 
Mashhad, northeast of Iran were studied in a cross-
sectional study. Three hundred and twenty six 
paraffin-embedded samples of breast carcinoma 
were chosen and confirmed pathologically. Five 
sections of 10-20 micron were extracted from 
paraffin blocks  in sterile conditions.
DNA extraction and PCR
Zylol-Ethanol method was used for 
deparaffinization of samples. For this purpose, 
paraffin-embedded samples were sliced in 
diameter of 20 micrometers using microtome 
and were kept in 1.5 ml micro-tubes. In the next 
step, 1 ml of zylol was added and the mixture 
was shaken for 30 min at 25 °C. Following that, 
it was centrifuged at 13000 rpm for 10 min. The 
supernatant was removed. This step was repeated 
for several times. Five hundred microliters of 
absolute ethanol was added to the pellet and it 
was shaken and centrifuged at 13000 rpm for 
10 min. In the final step, the supernatant was 
removed again and this step was repeated for the 
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second time. The pellet was kept at 25 °C so that 
it could lose ethanol but it was not allowed to 
dry completely.  PCR primers were designed by 
Gene Runner (Hastings Software Inc.) software 
according to the pattern sequences in GenBank.
β-Globin gene PCR to assess the quality of 
extracted DNA 
The quality of the extracted DNA from paraffin-
embedded tissue samples was assessed by primers 
of β-globulin gene. PC04  and  GH20 primers 
were used, which gave rise to PCR products of 
260 bp in length (Table 1).
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In order to amplify beta globin gene, the reaction 
mixture contained 0.8 μl of DNA, 0.4 μl of 
dNTPs (10mM), 0.8 μl of Taq DNA polymerase 
(5 U/μl), 1.6 μl of MgCl2 (25mM) , 10 pmol/μl 
of each primer, and  12.2 μl of  H2O (DNase-
RNase free). PCR program was 94 °C for 5 min; 
35 cycles of 94 °C for 30 s, 55 °C for 45 s, 72 °C 
for 45 s and a final extension of 72 C for 5 min.
 PCR-based method for HPV genotyping 
Genotyping was performed by PCR using virus-
specific primers for different subtypes (Table 2). 
The reaction mixture for PCR reaction of HPV 
types 6, 16, 18 and 31 contained 2 µl of DNA, 1x 
reaction buffer, 10 µmol dNTPs, 50 mmol MgCl2, 
10 pmol of each primers and 5 u/µl Taq DNA 
polymerase (Cinnagen, Iran). However, for type 
11, 25mmol MgCl2 and 3 µl of DNA was used. 
PCR program was 94 °C for 5 min; 35 cycles 
including 94 °C for 45 s; Melting temperatures of 
55 °C  for type 11, 57 °C  for type 6, 60.8 °C  for 
types 18 and 31, and 63 °C  for type 16; 72 °C for 
45 s and was followed by final extension of 72 °C 
for 10 min. It produced the PCR products of 360 
bp for type 11, 280 bp for type 6, 420 bp for types 
18 and 31, and 400 bp for type 16. Finally, PCR 
products were visualized on a 2% agarose gel. 
Using specific primers, samples, which produced 
the corresponding fragments, were considered 
positive for that type of HPV.
Table 2: Sequence of genotype-specific primers used in the PCR
ReferenceGenotypeSequencePrimer
(17)6
TAG TGG GCC TAT GGC TCGTCHPV  6 F
TCC ATT AGC CTC CAC GGG TGHPV 6 R
(17)11
GGA ATA CAT GCG CCA TGT GGHPV 11 F
CGA GCA GAC GTC CGT CCT CGHPV 11 R
(18)16
CAG GAC CCA CAG GAG CGA CCHPV 16- E6 F
ATC GAC CGG TCC ACC GAC CCHPV 16 –E6 R
(18)18
GCT TTG AGG ATC CAA CAC GGHPV 18 –E6 F
TGC AGC ACG AAT GGC ACT GGHPV18 – E6 R
(18)31
GAA ATT GCA TGA ACT AAG CTC GHPV 31-E6/E7 F
CAC ATA TAC CTT TGT TTG TCA AHPV 31-E6/E7 R
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Data Analysis
Frequency charts and diagrams together with 
SPSS v.20 (Chicago, IL, USA) was used for data 
explanation purposes.
Results
Results of beta-globin 
Overall, 326 samples were used. Age ranged 
between 24 and 74 years. The maximum age of 
positive samples was between 35 and 40 years. 
Samples from 326 patients with invasive breast 
carcinoma showed that 206 cases (63.2%) were 
positive for PCR of Beta-globin gene and 120 
cases (36.8%) were negative. Among positive 
samples, 54 cases (26.2%) were positive for HPV 
and 152 cases (73.8%) were negative. While 
among Beta globin-negative samples, 20 cases 
(16.7%) were HPV-positive and 100 (83.3%) 
were negative. Totally, 74 out of 326 samples 
(22.7%) were positive for HPV and 252 cases 
(77.3%) were HPV-negative.
Distribution of HPV genotypes 
Nineteen cases (25.7%) were positive for 
genotype 11, and 5 cases (6.8%) were positive 
for genotype 6. Two cases (2.7%) were found to 
be positive for both genotypes 6 and 11 (Fig.1). 
Samples were also screened for genotypes 16, 18 
and 31 and showed no positive result. Genotype 
of the virus was unknown for 48 cases (64.9%). 
In addition, there were 5 beta-globin negative 
cases among the 19 patients with genotype 11, 
and one out of five patients who was positive for 
genotype 6, was negative for beta-globin.
Distribution based on tumor grade in HPV 
positive specimens 
Among all HPV-positive cases, 1.4% had Grade 
A, 8.1% had grade B, 10.8% had grade C and 
79.7% had unknown grade.
Distribution according to involvement of 
axillary lymph node
Of total HPV-positive samples, 16.2% had 
axillary lymph node involvement, 1.4% had no 
involvement and for the remaining 82.4%, the 
involvement was unclear.
Fig. 1: Number of patients according to HPV 
genotypes
Discussion
Breast cancer is the most common malignant 
tumor in women. HPV is a small, non-enveloped 
virus containing DNA, which is highly specific 
for both species and tissue. Several studies 
supported the role of HPV in breast cancer. 
Seyed Alavi and colleagues studied the role of 
HPV infection in breast cancer and its correlation 
with clinical parameters. The role of HPV in 24 
cases (48%) of the total cases of breast cancer 
was identified. They also showed that 13 of them 
(26%) were infected with high-risk types of 
whereas in 8 cases (16%), they were infected with 
low-risk types of HPVs. In three breast cancer 
tissues (6%), both types of HPVs (High-risk and 
low-risk) were detected (3). Widschwendter et 
al. studied 11 patients with simultaneous cervical 
and breast cancers and observed that seven cases 
were positive for HPV (18). Kan et al. performed 
a study on DNA sequences of HPVs involved 
in breast cancers to assess possible correlations. 
They demonstrated that 24 samples (48%) of total 
50 samples were positive for HPV (19). Khan 
and colleagues studied the association of HPV in 
breast carcinoma in Japan. In 26 patients (21%), 
breast carcinomas were observed. Among them, 
Masoumeh Salehpour, et al.
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HPV type 16 was the most prevalent genotype, 
which has been considered as the main culprit 
(92%) for manifestation of disease (20). HPV 
DNA is highly associated with breast cancer (21, 
22). Yasmeen and colleagues conducted a study 
to evaluate the role of onco-proteins E6 and E7 
of HPV type 16 in cell invasion and metastasis 
of breast cancer. They reported that E6/E7 of 
genotype 16 is capable of making two invasive 
and metastatic cell lines: BT20 and MCF7 (23). 
HPV infection may have a significant role in the 
development of breast cancer (20, 24-27). Lee 
and colleagues used PCR method to study the 
role of HPV DNA in breast carcinoma. 24.49% 
of the cases of breast carcinomas were associated 
with HPV virus. In addition they also detected 40 
types of HPVs with HPV type 33, 18, 16 and 35 
being the most prevalent ones (28). 
Some studies, on the other hand, did not provide 
evidence in favor of the role of HPV in breast 
cancer. Wrede et al. and Gopalkrishna et al. 
conducted studies to evaluate the presence of HPV 
types 16 and 18 in breast carcinomas. However, 
none of the samples showed any correlations 
(29, 30).  A study was conducted to investigate 
the presence of HPV DNA in breast carcinoma 
in Korean women and the relationship between 
HPV and breast cancer progression. However, 
no noticeable correlations were observed (31). 
Throughout the last decade, several independent 
studies in different regions reported no significant 
correlation between HPV and the incidence and 
progression of breast cancer (32-35). The role of 
HPV in cancers such as uterine cervix has been 
widely accepted.
Conclusion 
The current study confirmed the role of HPVs 
in breast carcinoma among embedded tissue 
samples of invasive breast carcinoma in northeast 
of Iran. However, further investigations with a 
much larger sample size are required to validate 
the exact role of HPVs in the prevalence and 
progression of this cancer. 
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